Biotechnology Among last week’s notable news, US drug developer Crinetics Pharmaceuticals released surprisingly good Phase III clinical trial results for its paltusotine in acromegaly. Germany’s Immatics has entered into a collaboration with the USA’s Moderna to develop mRNA-based cancer therapies. US cell and gene based immune-oncology drug developer 2seventry bio last week announced it is cutting its work force by 40% as part of a cost-cutting restructuring, and that chief executive Nick Leschly is stepping down. Also of note, Alnylam received a positive US Food and Drug Administration (FDA) advisory committee vote for its ATTR-cardiomyopathy candidate Onpattro (patisiran). 17 September 2023